Ipca Laboratories Limited

NSE:IPCALAB.NS

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💻 Telehealth

Location

India

Market Cap

USD 3.97 B

Share Price

USD 15.63

Avg Daily Volume

262,019

Change (1 day)

-0.48%

Change (1 year)

16.23%

Change (YTD)

-21.05%

Ipca Laboratories Limited Enterprise Value to EBITDA (EV/EBITDA) on June 20, 2025: 22.05

Ipca Laboratories Limited Enterprise Value to EBITDA (EV/EBITDA) is 22.05 on June 20, 2025, a -3.84% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.

Ipca Laboratories Limited 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 34.79 on June 20, 2025, which is 57.78% above the current Enterprise Value to EBITDA (EV/EBITDA).
Ipca Laboratories Limited 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 22.05 on June 20, 2025, which is 0.00% below the current Enterprise Value to EBITDA (EV/EBITDA).
Ipca Laboratories Limited average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 27.67.

Daily

From:

To:

Zoom:

Key data

Date	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield	Market Capitalization

NSE: IPCALAB.NS

Ipca Laboratories Limited

CEO	Mr. Pranay Premchand Godha
IPO Date	Jan. 1, 1996
Location	India
Headquarters	125, Kandivli Industrial Estate
Employees	17,335
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies 💻 Telehealth

Description

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.